Stevenage Bioscience Catalyst Incubator Building G
About KaNDy TherapeuticsKaNDy Therapeutics was spun out from NeRRe Therapeutics in 2017, and at the same time, all formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 was transferred to KaNDy Therapeutics.
Founder, CSO, and COO: Mike Trower
CMO: Steve Pawsey
10 articles about KaNDy Therapeutics
Bayer Completes Acquisition of the UK-based Biotech Company KaNDy Therapeutics Ltd.
Bayer, a global leader in women’s healthcare, announced that, further to its press release on August 11, 2020, Bayer completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.
Forbion Portfolio Company, KaNDy Therapeutics, to Be Acquired by Bayer
Forbion, a leading European life sciences venture capital firm, announces that Bayer, a global leader in women’s healthcare, will acquire the UK-based biotech KaNDy Therapeutics Ltd.
Bayer to Acquire UK-Based Biotech KaNDy Therapeutics Ltd.
Bayer®, a leader in women’s healthcare, and KaNDy Therapeutics Ltd, a UK clinical-stage biotech company, announced that Bayer will acquire KaNDy Therapeutics Ltd. to expand its drug development pipeline in women’s healthcare.
With a $425 million upfront payment, Bayer bolstered its women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and its investigational treatment for menopause.
KaNDy Therapeutics announces initiation of Phase 2b trial of NT-814 for the treatment of troublesome post-menopausal symptoms
KaNDy Therapeutics, a clinical-stage company developing a potential breakthrough non-hormonal treatment for multiple debilitating symptoms of the menopause, today announces initiation of the Phase 2b clinical trial evaluating NT-814 in women with troublesome symptoms of the menopause.
KaNDy Therapeutics presents new compelling data with lead candidate NT-814 at The North American Menopause Society 2018 Annual Meeting
Treatment with NT-814 resulted in immediate improvements in bothersome post-menopausal symptoms
KaNDy Therapeutics Successfully Raises £25 Million in a Series C Financing
Funding to advance a breakthrough non-hormonal treatment for symptoms of the menopause, into a Phase 2b study in Q4 2018
KaNDy Therapeutics Announces Positive Clinical Data with Lead Candidate NT-814 for the Treatment of Symptoms of the Menopause
Phase Ib/IIa data showed rapid and highly significant reductions in the frequency and severity of hot flashes and the number of night time awakenings
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
New Biotech KaNDy Therapeutics Launches to Replace Hormonal Menopause Treatment